Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 32

References for PMC Articles for PubMed (Select 21858090)

1.

Epigenetic inactivation of the miR-124-1 in haematological malignancies.

Wong KY, So CC, Loong F, Chung LP, Lam WW, Liang R, Li GK, Jin DY, Chim CS.

PLoS One. 2011 Apr 22;6(4):e19027. doi: 10.1371/journal.pone.0019027.

2.

Widespread and tissue specific age-related DNA methylation changes in mice.

Maegawa S, Hinkal G, Kim HS, Shen L, Zhang L, Zhang J, Zhang N, Liang S, Donehower LA, Issa JP.

Genome Res. 2010 Mar;20(3):332-40. doi: 10.1101/gr.096826.109. Epub 2010 Jan 27.

3.

Targeting DNA methylation.

Issa JP, Kantarjian HM.

Clin Cancer Res. 2009 Jun 15;15(12):3938-46. doi: 10.1158/1078-0432.CCR-08-2783. Epub 2009 Jun 9.

4.

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDS Survival Study Group.

Lancet Oncol. 2009 Mar;10(3):223-32. doi: 10.1016/S1470-2045(09)70003-8. Epub 2009 Feb 21.

5.

Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines.

Qin T, Jelinek J, Si J, Shu J, Issa JP.

Blood. 2009 Jan 15;113(3):659-67. doi: 10.1182/blood-2008-02-140038. Epub 2008 Oct 17.

6.

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.

Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, List A, Fenaux P, Sanz G, Issa JP, Freireich EJ, Garcia-Manero G.

Cancer. 2008 Sep 15;113(6):1351-61. doi: 10.1002/cncr.23697.

7.

Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse.

Kroeger H, Jelinek J, Estécio MR, He R, Kondo K, Chung W, Zhang L, Shen L, Kantarjian HM, Bueso-Ramos CE, Issa JP.

Blood. 2008 Aug 15;112(4):1366-73. doi: 10.1182/blood-2007-11-126227. Epub 2008 Jun 3.

8.

High-throughput methylation profiling by MCA coupled to CpG island microarray.

Estécio MR, Yan PS, Ibrahim AE, Tellez CS, Shen L, Huang TH, Issa JP.

Genome Res. 2007 Oct;17(10):1529-36. Epub 2007 Sep 4.

9.

Decitabine and its role in the treatment of hematopoietic malignancies.

Plimack ER, Kantarjian HM, Issa JP.

Leuk Lymphoma. 2007 Aug;48(8):1472-81. Review.

PMID:
17701577
10.

Targeting the leukemia microenvironment.

Konopleva M, Andreeff M.

Curr Drug Targets. 2007 Jun;8(6):685-701. Review.

PMID:
17584025
11.

DNA methylation profiling of myelodysplastic syndrome hematopoietic progenitor cells during in vitro lineage-specific differentiation.

Hopfer O, Komor M, Koehler IS, Schulze M, Hoelzer D, Thiel E, Hofmann WK.

Exp Hematol. 2007 May;35(5):712-23.

PMID:
17577921
12.

RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis.

Boumber YA, Kondo Y, Chen X, Shen L, Gharibyan V, Konishi K, Estey E, Kantarjian H, Garcia-Manero G, Issa JP.

Cancer Res. 2007 Mar 1;67(5):1997-2005.

13.

Pharmacology of 5-Aza-2'-deoxycytidine (decitabine).

Momparler RL.

Semin Hematol. 2005 Jul;42(3 Suppl 2):S9-16. Review.

PMID:
16015507
14.

Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.

Al-Madhoun AS, van der Wilt CL, Loves WJ, Padron JM, Eriksson S, Talianidis I, Peters GJ.

Biochem Pharmacol. 2004 Aug 15;68(4):601-9.

PMID:
15276067
15.

Progesterone receptor gene inactivation and CpG island hypermethylation in human leukemia cancer cells.

Liu ZJ, Zhang XB, Zhang Y, Yang X.

FEBS Lett. 2004 Jun 4;567(2-3):327-32.

PMID:
15178346
16.

Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites.

Colella S, Shen L, Baggerly KA, Issa JP, Krahe R.

Biotechniques. 2003 Jul;35(1):146-50. No abstract available.

PMID:
12866414
17.

Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa.

Roman-Gomez J, Castillejo JA, Jimenez A, Cervantes F, Boque C, Hermosin L, Leon A, Grañena A, Colomer D, Heiniger A, Torres A.

J Clin Oncol. 2003 Apr 15;21(8):1472-9.

PMID:
12697869
18.

Inactivation of deoxycytidine kinase and overexpression of P-glycoprotein in AraC and daunorubicin double resistant leukemic cell lines.

Veuger MJ, Honders MW, Spoelder HE, Willemze R, Barge RM.

Leuk Res. 2003 May;27(5):445-53.

PMID:
12620296
19.

Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.

Kroep JR, Loves WJ, van der Wilt CL, Alvarez E, Talianidis I, Boven E, Braakhuis BJ, van Groeningen CJ, Pinedo HM, Peters GJ.

Mol Cancer Ther. 2002 Apr;1(6):371-6.

20.

Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia.

Stam RW, den Boer ML, Meijerink JP, Ebus ME, Peters GJ, Noordhuis P, Janka-Schaub GE, Armstrong SA, Korsmeyer SJ, Pieters R.

Blood. 2003 Feb 15;101(4):1270-6. Epub 2002 Oct 24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk